• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

    4/3/25 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

    The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.

    About Insulet Corporation:

    Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.

    ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250403205687/en/

    Investor Relations:

    June Lazaroff

    Senior Director, Investor Relations

    (978) 600-7718

    [email protected]

    Media:

    Angela Geryak Wiczek

    Senior Director, Corporate Communications

    (978) 932-0611

    [email protected]

    Get the next $PODD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    6/16/2025$365.00Buy
    Truist
    5/30/2025$380.00Buy
    Goldman
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care